Today, October 20, 2026: Hotel101 Global signs definitive binding agreements for a country-wide joint venture in Egypt, starting with an approx. 750-room Hotel101-Cairo West, Egypt. Hotel101-Cairo West is set to have approx. 750 rooms on a 15,984 sqm site in Hay Al Ashgar along Ahmed Zewail Road, only around ten minutes from the Giza Pyramids and the Grand Egyptian Museum (GEM). Hotel101-Cairo West is expected to generate 5.465 billion Egyptian pounds (US$102.09 million) in project value. Hotel101-Cairo West is expected to be one of the top 3 largest hotels by room count in Cairo, Egypt. Egypt is reported to have welcomed nearly 19 million tourists in 2025, while its total population is estimated at about 118.4 million. Hotel101 Global and IGI Holding joint venture signing ceremonyHotel101 Founder Mr Edgar “Injap” Sia II and Mr Khaled...

WUHU, China, Oct. 21, 2026 (GLOBE NEWSWIRE) — During the 2026 Chery International User Summit, the LEPAS L6 EV completed its first LEPAS Global Elegance Drive on October 19–20 as part of the inaugural LEPAS Global Elegant Lifestyle Week, held under the theme “TOGETHER IN ELEGANCE.” Bringing together 34 Elegant Driving Ambassadors from 15 countries, the approximately 700-kilometer journey from Shanghai to Wuhu passed through Tonglu, Qiandao Lake and Shexian, putting the L6 EV’s driving dynamics, ride comfort, intelligent parking, driving range and charging performance to the test across diverse road conditions.Experiencing Elegance on Every RoadOn day one, the convoy traveled from Shanghai to Qiandao Lake. The L6 EV’s 540° panoramic view system helped drivers navigate city traffic, while ADAS features eased highway driving. Thomas...

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova. The offering is expected to close on or about October 22, 2026, subject to the satisfaction...

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Disc from this offering are expected to be $450 million, before deducting underwriting discounts and commissions and other offering...

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026  and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. This first-in-class Antibody-Targeted Therapy Conjugate (“ATTC”) drug candidate comprises a highly selective and potent Kirsten rat sarcoma (“KRAS”) small molecule inhibitor payload conjugated to an anti-epidermal...

Where Classic Design Meets User Creativity: iCAUR Interprets “Classic Never Fades”At the 2026 iCAUR International User Summit, 20 customized vehicles were on display, including three official customization models. The concept design by a Hong Kong winner and the real-vehicle build by a Malaysian designer show how personal interests and regional culture can find expression in a vehicle’s design. Building on its classic design language, iCAUR extends personalization across different lifestyles with three official customized models: the V25 Game Changer, V23 Forge, and V27 Sun Roam. All three are slated for launch by early 2027. iCAUR has established official user clubs in nine countries and plans to extend its user clubs into more countries through its global Club Connect initiative in 2027. The brand will also set up dedicated areas...

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). BTDs are granted to innovative drugs or modified new drugs intended for the prevention or treatment of serious, life-threatening...

VANCOUVER, BRITISH COLUMBIA, Oct. 20, 2026 (GLOBE NEWSWIRE) — HI-VIEW RESOURCES INC. (“Hi-View” or the “Company”) (CSE: GXLD; OTCQB: GXLDF; FSE: B630) is pleased to announce that its Toodoggone land package, totalling >30,635 hectares, is now 100% owned. The Company has made all the final payments on all its optioned properties, with no further payments outstanding on any property within the package. R. Nick Horsley, CEO of Hi-View, commented, “We are now in full control of over 30,000 hectares of highly prospective ground in the Toodoggone District. Once all of our assays and data are interpreted, I believe we will have some of the highest-quality porphyry targets in the camp. It has long been our belief that the Toodoggone region will eventually be recognized as one of the richest mineral belts in North America, and Hi-View...